Retatrutide dosage chart

Reconstitution steps

1. 1Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall; avoid foaming.
3. 3Gently swirl/roll until dissolved (do not shake).
4. 4Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
5. 5Use within 4 weeks of reconstitution.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and lipohypertrophy.
• For doses >5 mg with 1.0 mL reconstitution, prepare multiple vials to obtain the required volume.
• For volumes >1.0 mL, split into 2–3 separate injections at different sites for better absorption.
• Inject slowly; wait a few seconds before withdrawing the needle to ensure full dose delivery.
• Document weekly dose, date, and injection sites to maintain consistency.
• Gradual titration is essential to minimize gastrointestinal side effects; never skip escalation steps.

How This Works

Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone. The peptide is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly dosing. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycemic control. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.

Clinical Benefits & Side Effects

Observations from Phase 2 human clinical trials.

• Exceptional weight loss: Patients with obesity (without diabetes) lost an average of 22–24% of body weight at 48 weeks on 8–12 mg doses.
• Glycemic control: In type 2 diabetes patients, HbA1c dropped by 1.3–2.0% (from ~8.0% to ~6.0%) with 4–12 mg doses; ~82% reached HbA1c ≤6.5%.
• Cardiometabolic improvements: Reductions in blood pressure, LDL cholesterol, waist circumference, and liver fat content (>80% resolution of hepatic steatosis on high doses).
• Universal response: 100% of participants on 8–12 mg achieved at least 5% weight reduction.
• Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhea, occurring primarily during dose escalation.
• Side effects were dose-dependent and transient; gradual titration (4-week intervals) significantly reduced GI discomfort compared to rapid escalation.
• No severe hypoglycemia or serious treatment-related adverse events reported in trials.
• Safety profile comparable to GLP-1 agonists when properly titrated.

Lifestyle Factors

Complementary strategies for optimal metabolic outcomes.

• Maintain a balanced, protein-forward diet with adequate micronutrients to support lean mass during weight loss.
• Combine resistance training (2–3×/week) with regular aerobic activity to preserve muscle and enhance metabolic adaptations.
• Prioritize sleep (7–9 hours) and stress management to support adherence and hormonal balance.
• Stay well-hydrated and monitor for signs of dehydration, especially during GI side effects.
• Work with healthcare providers to monitor metabolic markers (HbA1c, lipids, liver function) throughout the protocol.

Injection Technique

Subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol; allow to dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• For volumes >1.0 mL, split into 2–3 injections at different sites (e.g., left and right abdomen).
• Rotate sites systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy.
• Wait a few seconds after injecting before withdrawing needle to ensure full dose delivery.
• Dispose of used syringes immediately in an FDA-approved sharps container.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is not FDA-approved and is available only for research purposes. All information presented is based on published clinical trial data and is not intended to encourage off-label use.

Retatrutide dosage FAQs